People with advanced pancreatic cancer taking an experimental daily pill lived nearly twice as long as those receiving ...

By Julie Steenhuysen CHICAGO, May 31 (Reuters) - Revolution Medicine's experimental pancreatic cancer pill doubled survival ...

Philips plans to put its Bothell, Wash., campus up for sale, marking a significant moment for Washington state’s medical ...

A new report estimates speeding up FDA drug approvals by one year could generate over $10 trillion in economic value from ...

The young neurosurgeon in training couldn’t shake the sense of devastation. An 11-month-old girl died in his arms as he tried ...

The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who ...

FDA warns against using over-the-counter skin lightening products due to high levels of mercury or hydroquinone, which can ...

Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the ...

Renexxion plans to file new drug application (NDA) with the Food and Drug Administration (FDA) using future Phase 3 results ...

The approval relies on positive data from the POTOMAC Phase III trial.

The approved tablets are bioequivalent to Sutab Tablets, the reference listed drug (RLD) of Azurity Pharmaceuticals.

The growing popularity of peptides, many of which have not been authorized by the Food and Drug Administration, prompted ...